SEC Form 4 · accession 0001140361-17-016765
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — EVP, Research & Development
Period of report
Apr 23, 2017
Accepted (ET)
Apr 25, 2017 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 23, 2017 | A | 22,500 | $0.00 | A | 45,437 | D | |
| Common StockF3 | holding | — | — | — | 88,951 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.73 | Apr 23, 2017 | A | 67,500 | A | — | Apr 22, 2027 | Common Stock | 67,500 | 67,500 | D |
Explanation of responses
- F1Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
- F2Includes 35,000 RSUs.
- F3The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.
- F4The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.